AgomAb Therapeutics NV American Depositary Shares Market Cap ($368.87 Million)
Market Cap & Net Worth: AgomAb Therapeutics NV American Depositary Shares (AGMB)
AgomAb Therapeutics NV American Depositary Shares market cap. AgomAb Therapeutics NV American Depositary Shares (NASDAQ:AGMB) has a market capitalization of $368.87 Million ($368.87 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13492 globally and #3286 in its home market, demonstrating a -19.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AgomAb Therapeutics NV American Depositary Shares's stock price $7.49 by its total outstanding shares 49247975 (49.25 Million).
AgomAb Therapeutics NV American Depositary Shares Market Cap History (2026–2026)
AgomAb Therapeutics NV American Depositary Shares market cap history from 2026 to 2026. Data shows growth from $368.87 Million to $368.87 Million (0.00% CAGR). Check AGMB stock price for real-time trading data and today's change.
AgomAb Therapeutics NV American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AgomAb Therapeutics NV American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see AgomAb Therapeutics NV American Deposita operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AGMB by Market Capitalization
Companies near AgomAb Therapeutics NV American Depositary Shares in the global market cap rankings as of October 31, 2026. See AgomAb Therapeutics NV American Deposita (AGMB) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to AgomAb Therapeutics NV American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of AgomAb Therapeutics NV American Depositary Shares (2026–2026)
Market capitalization of AgomAb Therapeutics NV American Depositary Shares from 2026 to today. Between 2026 and today, AgomAb Therapeutics NV American Depositary Shares's market cap moved from $368.87 Million to $ 368.87 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $368.87 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of AgomAb Therapeutics NV American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $368.87 Million USD |
| MoneyControl | $368.87 Million USD |
| MarketWatch | $368.87 Million USD |
| marketcap.company | $368.87 Million USD |
| Reuters | $368.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more